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Abstract
LIN28, an evolutionarily conversedRNAbinding protein which canbindtothe terminalloopsoflet-7family microRNA precursors
and block their processing to maturation, is highly expressed in several subsets of tumors that carry poor prognoses, such as
ovarian carcinoma, hepatocellular carcinoma, colon carcinoma and germ cell carcinoma. However, there has been no study on
the expression of LIN28 in glioma tissues or their importance as a prognostic predictor of glioma patients. This study aimed to
examine the expression of LIN28 in glioma and correlate the results to patient outcome. We found that LIN28 expression was
significantly higher in the group of patients with a poor prognosis compared to patients with a good prognosis by gene
microarray.Log-rankanalysisshowedpatientswithhigherLIN28expressionlevelintumorhadashorterprogression-freesurvival
and overall survival times compared to those with lower LIN28 expression level. Similar results were also obtained from the tissue
microarrayanalysis.Univariateandmultivariateanalysesshowedhigh LIN28 expression wasan independent prognostic factorfor
a shorter progression-free survival and overall survival in GBM patients. Furthermore in vitro experiments showed that down-
regulation ofLIN28inU251andU373cellscausedcell cycle arrestin theG1phase, delayedcellproliferation, increasedapoptosis,
and resulted in fewer colonies compared to controls. Summarily, our data provides a potential target for cancer therapy as an
approach to overcome the poor options currently available for GBM patients.
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Introduction
Gliomas are the most common primary brain tumor in adults,
with an incidence rate of approximately five per 100,000 person-
years annually worldwide. Approximately 70% of gliomas are
malignant gliomas, and the most frequent and lethal cancers
originate in the central nervous system (CNS) with a high
recurrence and mortality rate [1]. The 5-year survival rate is
approximately 20% for patients with glioma, but ,3% for patients
with glioblastoma multiforme (GBM), the most biologically
aggressive subtype of gliomas. Despite aggressive surgery, radia-
tion, and chemotherapeutic options, the life expectancy of patients
with GBM is still poor with a median overall survival of
approximately 12–15 months after diagnosis [2].
Substantial efforts have been taken to identify molecular
markers and therapeutic targets that could help to achieve a
better prognosis. Several candidate genes, such as EGFR [3],
SOX2 [4], and VEGF [5], have been implicated in the
oncogenesis or progression of GBM. These genes could play
important roles in the treatment of this severe disease. New
therapeutics against these targets have potential utility as effective
clinical treatments. Thus, a better understanding of the mecha-
nisms involved in regulating tumor growth requires the identifi-
cation of novel genes associated with glioma.
LIN28 is an evolutionarily conversed RNA binding protein that
can bind to the terminal loops of let-7 family microRNA (miRNA)
precursors and block their processing to maturation [6–8]. Several
oncogenes are known to be targets of the let-7 miRNA family,
including Ras [9], c-Myc [10], and Hmga2 [11], and the
repression of let-7 has been linked to several types of tumor, such
as lung [9,10], breast [12], and ovarian [13–15] cancer. It has
been reported that LIN28 is highly expressed in several subsets of
tumors that carry poor prognoses, such as ovarian carcinoma [13–
15], hepatocellular carcinoma [16–18], colon carcinoma [19,20],
and germ cell carcinoma [21–23]. Based on these observations,
LIN28 has been shown to be functional in the post-transcriptional
regulation of the let-7 miRNA family and is postulated to be
oncogenic through repression of let-7 family miRNAs as well as
depression of let-7 targets. However, whether LIN28 is related to
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e86446Table 1. Demographic and clinicopathological characteristics of the patients (n=17).
Characteristics Value Lin28 Expression Low Lin28 Expression High
Number of Patient 17 12 5
Age(years)
Mean 6 S.D. (Median) 41.00611.64 (41)
#50 13(76.5%) 12 1
.50 4(23.5%) 0 4
Gender
Male 13(76.5%) 9 4
Female 4(23.5%) 3 1
Seizure
Present 4(23.5%) 3 1
Absent 13(76.5%) 9 4
IICP
Present 9(52.9%) 5 4
Absent 8(47.1%) 7 1
Cystic degeneration
Present 6(35.3%) 3 3
Absent 11(64.7%) 9 2
Necrosis on MRI
Present 6(35.3%) 2 4
Absent 11(64.7%) 10 1
Border on MRI
Clear 5(29.4%) 5 0
Unclear 12(70.6%) 7 5
MTD(cm)
Mean 6 S.D.(Median) 4.5861.31 (4.24)
,5 11(64.7%) 8 3
$5 6(35.3%) 4 2
Resection degree
Gross total resection 14(82.4%) 10 4
Subtotal resection 3(17.6%) 2 1
Tumor grade and pathological category
WHO Grade I 2(11.8%)
Pilocytic astrocytoma 2 2 0
WHO Grade II 9(52.9%)
Astrocytoma 4 4 0
Oligodendroglioma 5 3 2
WHO Grade III 2(11.8%)
Anaplastic astrocytoma 2 1 1
WHO Grade IV 4(23.5%)
GBM 4 2 2
Adjuvant Chemotherapy
Present 13(76.5%) 10 3
Absent 4(23.5%) 2 2
Adjuvant Radiotherapy
Present 10(58.8%) 8 2
Absent 7(41.2%) 4 3
Survival status
Alive 10(58.8%) 9 1
Dead 7(41.2%) 3 4
Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter; GBM, glioblastoma multiforme.
doi:10.1371/journal.pone.0086446.t001
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currently unclear.
Based on the complete sequencing of the human genome as well
as several high-throughput genomic technologies, The Cancer
Genome Atlas (TCGA) has defined three main pathways involved
in GBM: the RTK/RAS/PI3K signaling pathway as well as the
p53 and RB tumor suppressor pathways. The frequencies of
somatic alterations in these pathways have been shown to be 88%,
87%, and 78%, respectively [24]. Previous studies have demon-
strated that several upstream genes involved in these pathways,
Table 2. Demographic and clinicopathological characteristics of the patients(n=90).
Characteristics Value Lin28 Expression Low Lin28 Expression High
Number of Patient 90 25 65
Age(years)
Mean 6 S.D. (Median) 50.82616.23 (54)
#50 32(35.6%) 11 21
.50 58(64.4%) 14 44
Gender
Male 61(67.8%) 16 45
Female 29(32.2%) 9 20
Seizure
Present 11(12.2%) 3 8
Absent 79(87.8%) 22 57
IICP
Present 39(43.3%) 10 29
Absent 51(56.7%) 15 36
Cystic degeneration
Present 19(21.1%) 9 10
Absent 67(74.4%) 14 53
Unknown 4(4.4%) 2 2
Necrosis on MRI
Present 15(83.3%) 7 8
Absent 75(16.7%) 18 57
Border on MRI
Clear 17(18.9%) 4 13
Unclear 41(45.6%) 12 29
Unknown 32(35.5%) 9 23
MTD(cm)
Mean 6 S.D.(Median) 4.3561.23 (4.64)
,5 37(41.1%) 12 25
$5 52(57.8%) 12 40
Unknown 1(1.1%) 1 0
Resection degree
Gross total resection 68(75.6%) 19 49
Subtotal resection 19(21.1%) 5 14
Partial resection 3(3.3%) 1 2
Adjuvant Chemotherapy
Present 64(71.1%) 19 45
Absent 26(28.9%) 6 20
Adjuvant Radiotherapy
Present 63(70.0%) 21 42
Absent 27(30.0%) 4 23
Survival status
Alive 5(5.6%) 4 1
Dead 85(94.4%) 21 64
Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter.
doi:10.1371/journal.pone.0086446.t002
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27]. The purported link between LIN28 and glioma was even
highlighted by the recent identification of the role of Let-7 miRNA
in GBM: let-7 miRNA can reduce the in vitro proliferation and
migration of GBM cell lines and reduce the size of xenograft
tumors in nude mice [28]. However, the effects of LIN28 on the
prognosis of glioma patients remain unknown.
In this study we used gene and tissue microarrays to detect the
correlation between the LIN28 expression level and prognosis of
glioma patients, and then performed cytological experiments to
define the role of LIN28 in glioma tumorigenesis. We found that
the expression of the LIN28 gene was significantly different
between the patient group with a good prognosis and the group
with a poor prognosis, indicating that LIN28 may be a predictor of
survival in glioma patients. The cytological experiments further
illustrated the role of LIN28 in the proliferation of glioma cells.
Materials and Methods
Tissue Samples and Ethics Statement
The study protocol and acquisition of tissue specimens were
approved by the Specialty Committee on Ethics of Biomedicine
Research, Second Military Medical University, and complied with
the National Regulations on the Use of Clinical Samples in China.
Glioma tissue specimens were obtained from archived tissue
samples from patients who underwent surgical treatment at
Changzheng Hospital during the period from January 1999 to
December 2010. These patients or their legal guardian provided
written informed consent to the surgical procedures and gave
permission to use resected tissue specimens for research purposes.
A diagnosis of glioma was confirmed pathologically by two
independent, experienced pathologists.
Gene Expression Microarray
For gene expression microarray analysis, tumor tissue from 17
glioma patients was assessed on an Affymetrix Array platform
(Santa Clara, CA). The demographic and clinicopathological
characteristics of the 17 glioma patients are shown in Table 1. The
sample preparation and microarray hybridization were performed
based on the manufacturer’s standard protocols. Briefly, 1 mgo f
total RNA from each sample was amplified and transcribed into
fluorescent cRNA using the manufacturer’s labeling protocol. The
labeled cRNAs were hybridized onto the Affymetrix U133 plus
2.0. After washing the slides, the arrays were scanned by
Figure 1. Unsupervised two-dimensional cluster analysis of 17 gliomas. A. Two-dimensional presentation of transcript ratios for 17 glioma
samples. The cutoffs of fold changes $2.5 and Student’s t-test p#0.011 were used to select the genes with significantly different expression. There
were 75 significant genes identified across the group. Each row represents a tumor and each column a single gene. As shown in the color bar, red
indicates a high level of expression of mRNA in the tumor, compared to the reference level of mRNA, and green indicates a low level of expression.
The asterisk represents the gene LIN28. The dotted line is the previously determined threshold between a good-prognosis signature and a poor-
prognosis signature. B. The total duration of follow-up for all patients.
doi:10.1371/journal.pone.0086446.g001
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divided into ‘‘high’’ ($1) and ‘‘low’’ (,1) describing the expression
level of LIN28. Differentially expressed genes were identified
through fold change filtering.
Hierarchical clustering was performed using the multiple
experiment viewer (MeV) 4.7.1 software (http://www.tm4.org/
mev/). Gene ontology (GO) analysis and pathway analysis were
performed using the standard enrichment computation method.
Differentially regulated genes are represented in the links predicted
using STRING (http://string.embl.de/).
Tissue Microarray Construction and
Immunohistochemistry
Paraffin-embedded tissues were acquired from 90 GBM
patients. The demographic and clinicopathological characteristics
of the patients are shown in Table 2. Tissue microarrays of these
sample specimens were constructed as previously described [29].
Immunohistochemical staining using a polyclonal anti-LIN28
antibody (Abcam, San Diego, CA) was performed according to the
manufacturer’s instructions. The intensity and extent of staining
were evaluated by two independent pathologists blinded to the
clinicopathological data of the patients. Staining intensity in the
cytoplasm was graded using a scale from 0 to 3 (0, no
immunostaining; 1, light brown color; 2, medium brown color,
and 3, dark brown color). The percentage of positively stained cells
was scored as follows: 0, no staining; 1, #50% of the tumor cells;
2, 50–90% of the tumor cells; 3, .90% of the tumor cells. The
final score, regarded as the expression level of LIN28, was the
product of intensity and percentage scores, and was classified as
follows: strong (+++, final score .6), moderate (++, final score=4–
6), weak (+, final score=1–3), or null (2, final score=0). For
analysis, LIN28 expression was divided into ‘‘high’’ (++ and +++)
and ‘‘low’’ (+ and 2). All discrepancies in scoring were reviewed
and a consensus was reached between the two pathologists.
Cell Culture
The human glioblastoma cell lines U251 and U373 were
obtained from the American Type Culture Collection (ATCC)
and maintained as subconfluent monolayers at 37uC and 5% CO2
in Dulbecco’s modified Eagle’s medium/Ham’s F-12 nutrient
mixture (DMEM/F-12), containing 15 mM HEPES and 2.5 mM
L-glutamine. The medium was supplemented with 5% heat
inactivated equine serum, 500 ng/ml hydrocortisone, 21.5 ng/ml
epidermal growth factor (EGF), 10 mg/ml insulin, 100 ng/ml
cholera toxin, and 10 mg/ml gentamicin.
A target sequence for the small hairpin RNA (shRNA) for
LIN28 was used (59-CTGTAACGTTGCGAATGGTAT-39). A
retrovirus expressing shRNA specific to LIN28 was used to infect
U251 and U373 cells. Briefly, a retroviral vector containing a
specific shRNA, pHCMV-G, or pCMV-dR8.9 were co-transfect-
ed into 293T cells, and the viral supernatants were collected to
infect U251 and U373 cells. Single clonal cells were then selected,
expanded, and screened for the down-regulation of LIN28.
Figure 2. The expression of LIN28 and its correlation with overall survival and progression-free survival of glioma patients. A. The
expression difference of LIN28 between the good prognosis group and poor prognosis group by gene microarray analysis. B. Immunohistochemical
staining of LIN28 in GBM tissues. C,D. The Kaplan-Meier survival curve for overall survival and progression-free survival for 90 GBM patients stratified
by LIN28 expression.
doi:10.1371/journal.pone.0086446.g002
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To confirm the expression of LIN28 in U251 and U373 cells,
the reactions were conducted on an iCycler iQ (BioRad). Each
25 ml PCR reaction included SYBR Green Supermix (BioRad)
with 0.4 mM each of dNTP, 50 U/ml iTaq DNA polymerase,
6m MM g
2+ SYBR Green I, and 20 nM fluoroscein. The reaction
mixture also contained cDNA from U251 and U373 cells and the
forward and reverse primers specific for the gene of interest. The
efficiency of each primer set was calculated using a standard curve.
Dilutions of cDNA ranging from 0.37–30 ng were prepared and
the cycle threshold (Ct) values for the reactions were plotted
against the cDNA concentrations. The comparative cycle thresh-
old method (2
2DDCt) was used to quantify gene expression. Fold-
change values represent an average of three separate experiments.
b-actin served as the internal control in each qRT-PCR reaction.
All measurements were performed in triplicate. The sequences of
the primer pairs were as follows: LIN28 59-GGAATCGTGG-
TCTCTCACTCG-39 and 59-GTGTGATGTCCGGACTGT-
CAT-39; b-actin 59-AGCGAGCATCCCCCAAAGTT-39 and
59- GGGCACGAAGGCTCATCATT-39.
Western Blot
Cells were lysed by vortexing on ice in 50 mM Tris (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF,
and 1% protease inhibitor cocktail (Sigma). Protein concentrations
were determined using the Bradford method (BioRad). Total
cellular protein (50 mg) was separated on SDS-polyacrylamide gels
and then transferred to polyvinyldifluoride (PVDF) membranes
(Millipore). For immunodetection, the membranes were incubated
in blocking buffer (5% non-fat dry milk dissolved in Tris-buffered
saline solution with 0.05% Tween 20) for 60 min at room
temperature to block all non-specific binding sites. The mem-
branes were then incubated with the primary antibody diluted in
blocking buffer for 60 min at room temperature. After anti-LIN28
(1:500) or anti-GAPDH (1:1000) antibody (Abcom, Cambridge,
UK) incubation the membranes were washed in Tris-buffered
saline-Tween (TBS-T). The membranes were then incubated with
a goat anti-mouse horseradish peroxidase-conjugated secondary
antibody (1:20,000, Abcom, Cambridge, UK) for 60 min at room
temperature before being washed again in TBS-T. Proteins were
visualized with the enhanced chemiluminescence plus (ECL+)
system (Amersham) on a FluorChem 8900 imaging system (Alpha
Innotech). All antibodies were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). GAPDH was used as a
loading control.
Cell Cycle Analysis by Flow Cytometry
Cells were harvested and fixed with 75% alcohol overnight at
220uC, and then washed the next day with phosphate-buffered
saline (PBS) prior to incubation with 0.2 mg/ml RNase (Sigma, St.
Louis, MO) and 10 mg/ml propidium iodide at 37uC for 30 min.
At least 15,000 stained cells were analyzed and the percentage of
cells in G0/G1, S, and G2/M phases was determined by a FACS
Calibur flow cytometer (Becton-Dickinson, Franklin, NJ). Exper-
iments were performed in triplicate.
Colony Formation Assays
Six-well plates with underlayers consisting of 0.8% agar
medium were prepared. At 24 h post-transfection, cells were
plated at a density of 1,000 cells per well in plates and allowed to
grow for 2 weeks prior to fixation in ice-cold methanol and
Giemsa’s stain. The survival fraction was determined by dividing
the number of shLIN28 colonies by the number of control cell
colonies. Colonies were counted under a light microscope.
Experiments were performed in triplicate.
Cell Proliferation Assays
U251 cells and U373 cells transfected with LIN28 shRNA or a
negative control lentivirus were plated at a density of 1,000 cells
per well in collagen-coated 96-well plates. The Cell Counting Kit-
8 (CCK-8; Dojindo, Kumamoto, Japan) was used to perform cell
proliferation assays. Briefly, 10 ml CCK-8 solution was added to
each well and incubated at 37uC for 2 h. Optical density (OD) was
then measured at 450 nm. Experiments were performed in
triplicate.
Cell Apoptosis Assays
The apoptotic response was measured using the flow cytometric
method. Treated and untreated cells were harvested, washed once
with PBS, and then fixed in 70% ethanol. Ethanol-fixed cells were
stained with propidium iodide (16.5 mg/ml) in PBS after RNase
(0.03 mg/ml) digestion. Samples were analyzed with a FACS
Calibur (Becton-Dickinson, Franklin, NJ). For each sample,
10,000 cells were analyzed. Experiments were performed in
triplicate.
Table 3. Univariate analysis of factors associated with survival
and progression(n=90).
Variable GBM
OS PFS
HR 95% CI P HR 95% CI P
Age (.50 vs. #50 y) 1.869 1.166–
2.997
0.009 1.700 1.065–
2.713
0.026
Lin28 (High vs. low) 1.845 1.092–
3.117
0.022 2.052 1.215–
3.466
0.007
IICP (Yes vs. no) 0.929 0.605–
1.428
0.738 0.869 0.562–
1.345
0.530
MTD (,5v s$5 cm) 0.645 0.426–
0.977
0.039 0.804 0.538–
1.202
0.287
Cystic Degeneration
(Yes vs. no)
0.683 0.448–
1.041
0.076 0.762 0.489–
1.187
0.229
Necrosis (Yes vs. no) 0.956 0.525–
1.738
0.882 1.139 0.629–
2.064
0.668
Chemotherapy
(Yes vs. no)
0.727 0.457–
1.156
0.178 0.837 0.523–
1.341
0.460
Radiotherapy
(Yes vs. no)
0.551 0.346–
0.878
0.012 0.546 0.341–
0.875
0.012
Resection Degree NA NA 0.029 NA NA 0.047
Subtotal vs. Total 0.713 0.420–
1.209
0.210 0.645 0.379–
1.099
0.107
Partial vs. Total 3.837 1.178–
12.496
0.026 2.824 0.874–
9.122
0.083
Seizure (Yes vs. no) 0.820 0.407–
1.651
0.578 1.064 0.531–
2.131
0.862
Gender(Female vs. male) 0.821 0.519–
1.298
0.398 0.719 0.448–
1.154
0.171
Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter;
NA, not applicable; HR, Hazard ratio; OS, overall survival; PFS, progression-free
survival.
doi:10.1371/journal.pone.0086446.t003
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For each patient, median overall survival (OS) and progression-
free survival (PFS) were recorded. PFS was defined as the time
from initial surgical diagnosis to tumor progression based on
magnetic resonance imaging (MRI) or death from glioma. OS was
defined as the time from the initial surgical diagnosis to death. PFS
and OS curves were calculated using the Kaplan-Meier method
and compared using the log-rank test. Univariate and multivariate
analyses were performed by a stepwise backward Cox regression
model. Factors with a result of p,0.2 in the univariate analysis
were added into the multivariate analysis.
Data from the experiments on cultured cells were expressed as
mean 6 standard deviation (S.D.) and statistical significance
between the groups was analyzed with one-way analysis of
variance (ANOVA), followed by Dunnett’s t-test for post-hoc
pair-wise comparisons. The SPSS 16.0 software (SPSS Inc.,
Chicago, USA) was used for the statistical analysis and the level of
significance was set as p,0.05.
Results
Gene Microarray Analysis
Glioma tissue samples from 17 patients were cultured and the
cRNAs were subsequently prepared and hybridized onto the
Affymetrix U133 plus 2.0 array. Of the 54675 genes represented
on the array, 75 genes displayed at least a 2.5-fold increase or
decrease in expression at the p,0.011 level with a false discovery
rate. Of these, 43 genes were upregulated, while 32 genes were
down-regulated in tumors from patients in the poor prognosis
group compared to patients from the patient group with a good
prognosis (Fig. 1). The criteria used to define poor versus good
prognosis gliomas included the survival status at 96 months post-
procedure.
Gene Ontology (GO) Analysis
To elucidate the relationship between differential gene expres-
sion patterns, we examined the functional bias of the 75
differentially expressed transcripts according to GO classifications.
These differentially expressed transcripts were grouped into 28
GO based on biological process GO terms. The 10 most enriched
GO terms (gene count .10) included organ development, system
development, multicellular organismal process, anatomical struc-
ture development, immune system process, blood vessel morpho-
genesis, anatomical structure formation involved in morphogen-
esis, immune response, blood vessel development, and response to
metal ions (Table S1). Analyses of GO also indicated that there
were 6 GO terms identified by cellular component classification,
including the extracellular region part, the extracellular space,
extracellular matrix (ECM), MHC class II protein complex,
intracellular part and intracellular organelle part (Table S2), as
well as 5 GO terms identified by molecular function classification,
including receptor binding, signaling molecule, other transcription
factor, MHC class II receptor activity, and extracellular matrix
binding (Table S3).
High LIN28 Expression Correlates with Poorer Survival of
Glioma Patients
Our results showed that the expression levels of LIN28 in the
group of patients with a poorer prognosis were significantly higher
than those in the group of patients with a good prognosis by gene
microarray analysis (Median LIN28 expression: 1.23 vs. 0.38,
respectively; p=0.011; Fig. 2A, Table S4).
To confirm the results obtained from our microarray analysis,
we used a collection of tissues from 90 GBMs and evaluated
LIN28 expression by means of immunohistochemistry (Fig. 2B).
Similar findings were observed in GBM patients stratified by
LIN28 expression, indicating that patients expressing high LIN28
levels had a significantly shorter OS and PFS relative to patients
expressing low LIN28 levels (median OS: 10 vs. 14 months,
p=0.015; and median PFS: 8 vs. 12 months, respectively;
Table 4. Multivariate analysis of factors associated with survival and progression (n=90).
Survival* Median Survival (months, 95% CI) HR 95% CI P
OS
Age (.50 vs. #50 y) 10(8.357–11.643) 15(8.845–21.155) 2.053 1.267–3.326 0.003
Lin28 (High vs. low) 10(8.182–11.818) 14(10.467–17.533) 1.874 1.085–3.237 0.024
Resection NA NA NA NA 0.018
Subtotal vs. Total 13(8.734–17.266) 10(8.271–11.729) 0.651 0.382–1.109 0.114
Partial vs. Total 2(0.400–3.600) 10(8.271–11.729) 3.878 1.164–12.918 0.027
Radiotherapy (Yes vs. No) 12(10.360–13.640) 9(5.998–12.002) 0.541 0.336–0.873 0.012
MTD (,5v s$5 cm) 10(7.816–12.184) 11(9.431–12.569) 0.575 0.369–0.895 0.014
PFS
Age (.50 vs. #50 y) 7(5.135–8.865) 10(6.183–13.817) 1.865 1.151–3.022 0.011
Lin28 (High vs. low) 8(6.044–9.956) 12(4.350–19.650) 1.798 1.040–3.110 0.036
Resection NA NA NA NA 0.036
Subtotal vs. Total 12(7.734–16.266) 7(5.531–8.469) 0.546 0.316–0.944 0.030
Partial vs. Total 1(NA) 7(5.531–8.469) 2.060 0.625–6.785 0.235
Radiotherapy (Yes vs. No) 10(6.736–13.264) 7(3.183–10.817) 0.445 0.268–0.739 0.002
Gender(Female vs. male) 9(5.883–12.117) 7(4.449–9.551) 0.589 0.353–0.984 0.043
Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter; NA, not applicable.
*Variables were adopted for their prognostic significance by univariate analysis (P#0.2).
doi:10.1371/journal.pone.0086446.t004
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that a high expression of LIN28 was a risk factor for a shorter OS
and PFS (HR=1.845, p=0.022; and HR=2.052, p=0.007,
respectively; Table 3). Furthermore, the Cox regression analysis
revealed that high LIN28 expression was an independent
prognostic factor for both OS and PFS in GBM patients (median
OS: 10 vs. 14 months, p=0.024; and median PFS 8 vs. 12
months, p=0.036, respectively; Table 4).
Lentivirus-based RNAi of LIN28 Down-regulates LIN28
Expression
To investigate the role of LIN28 in the growth of human glioma
cells, we generated LIN28-knockdown stable cell lines as well as
the corresponding control and normal glioma cell lines (designated
as shLIN28, control, and MOCK, respectively). As shown in
Figures 3A and B, both LIN28 mRNA and protein expression
were significantly reduced by RNAi-mediated LIN28 knockdown
in U251 and U373 cell lines (p,0.05).
RNAi of LIN28 Suppresses Glioma Cell Growth and
Colony Formation in vitro
To assess the role of LIN28 in the growth of human glioma
cells, we performed MTT assays to examine the cell proliferation
of U251 cells and U373 cells after transfection with LIN28
shRNA. As shown in Figures 3C and D, down-regulation of
LIN28 by RNAi caused a significant delay of both U251 and
U373 cell growth after 3 days post-transfection compared to the
negative control (p,0.05).
To determine the effects of LIN28 in human glioma tumori-
genesis in vitro, we assayed the colony formation of U251 and
U373 cells in soft agar. As shown in Figures 3E and F, reduction of
LIN28 in U251 and U373 cells lines remarkably reduced the
number of colonies from 27.364.5 to 1.361.5 (p,0.01) and
51.064.6 to 11.064.0 (p,0.01) compared to control, respectively.
These results indicated that LIN28 might be involved in human
glioma cell growth and tumorigenesis in vitro.
Figure 3. Decreased expression of LIN28 mRNA and protein in human glioma cells by siRNA. U251 and U373 cells were transfected with
lentivirus-based small interfering RNA (shLIN28) or the empty plasmid (as the negative control, Control). A,B. RT-PCR and Western blot analysis were
used to detect the LIN28 mRNA and protein expression levels in U251 and U373 cells. C,D. CCK-8 assays were used to determine the effects of LIN28
knockdown on cell proliferation in U251 and U373 cells. E,F. The effects of LIN28 knockdown on cell colony formation in U251 and U373 cells.
* p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0086446.g003
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LIN28 has been shown to regulate the translation of cell cycle
proteins in other cells types [27]. The cell cycle distribution is
highly indicative of changes in cell proliferation, apoptosis,
differentiation, and senescence, which may lead to carcinogenesis.
Thus, we assess LIN28-mediated changes in the cell cycle. As
shown in Figure 4A, suppression of LIN28 with shRNA led to a
modest but consistent increase in the population of U251 cells in
G1 phase compared to control (51.6760.70% vs. 41.6261.67%,
respectively). This was accompanied by a decreased percentage of
cells in S phase compared to control (37.4561.97% vs.
52.5265.66%, respectively). In U373 cells, suppression of LIN28
also caused an increase in the percentage of cells in G1 phase
(70.9560.95% vs. 63.9360.41%) and a decreased percentage in S
phase (15.9260.92% vs. 30.5461.39%) compared to control,
respectively. These results indicate that LIN28 may play an active
role in glioma cell cycle progression, which, in turn, accelerates cell
proliferation.
To determine the role of LIN28 in apoptosis of human glioma
cells, we performed apoptosis assays using a flow cytometric
method. As shown in Figure 4B, apoptotic cells were significantly
increased from 15.4561.18% to 19.7661.42% in U251 cells
(p,0.05) and from 16.9262.07% to 26.0762.04% in U373 cells
(p,0.05) after transfection with LIN28 shRNA relative to control,
respectively. These results indicate that LIN28 might be involved
in human glioma cell apoptosis.
Discussion
LIN28, a highly conserved RNA-binding protein, was initially
described as a regulator of developmental timing sequence in
Caenorhabditis elegans [30]. The mammalian homolog of LIN28 is
also implicated in developmental processes. It is highly
expressed in embryonic stem cells and down-regulated during
differentiation [31]. LIN28 consists of a cold shock domain
(CSD) and a pair of retroviral-type CCHC zinc fingers [30,31],
which bind to the terminal loops of the precursors of let-7
family miRNAs and block their processing into mature miRNAs
[6–8]. Let-7 is known to regulate several oncogenes, including
Ras [9], c-Myc [10], and Hmga2 [11], and the repression of
let-7 has been linked to several tumor types, such as lung
[9,10], breast [12], and ovarian cancer [13–15]. Thus, let-7
may be involved in tumor inhibition. In addition, LIN28 has
been shown to be involved in the post-transcriptional regulation
of the let-7 miRNA family, and therefore LIN28 is likely to be
involved in tumor occurrence and development [16].
Figure 4. Cell cycle distribution and apoptosis of human glioma cells with shRNA-mediated knockdown of LIN28. A. Suppression of
LIN28 leads to the cell cycle arrest of U251 and U373 cells treated with LIN28 shRNA in the G1 phase, accompanied by a decreased population in S
phase. B. Relative to the controls, the percentage of apoptotic cells was significantly increased in U251 cells treated with LIN28 shRNA. The changes
were also significant in U373 cells. * p,0.05.
doi:10.1371/journal.pone.0086446.g004
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reprogram human somatic fibroblast to pluripotency together
with OCT4, SOX2, and NANOG, while the overexpression of
LIN28 induced malignant transformation of cells [16]. A
previous study found high expression of LIN28 in approxi-
mately 15% of more than 500 primary tumors or cell lines
analyzed [16], especially in the subset of tumors that were
poorly differentiated and had a worse prognosis, such as blast
phase chronic myeloid leukemia [16], hepatocellular carcinoma
(HCC) [16–18], ovarian carcinoma [13–15], colon carcinoma
[19,20], and germ cell carcinoma [21–23]. Furthermore,
overexpression of LIN28 is associated with high serum a-
fetoprotein (AFP) levels and high-grade HCC tumors [17] as
well as a reduced overall survival and increased probability of
tumor recurrence in colon carcinoma [19].
In the present study, we examined the expression of LIN28
by gene microarray analysis and immunohistochemistry of a
tissue microarray and found that high expression of LIN28 was
associated with reduced OS and PFS. Univariate and multi-
variate analyses showed that LIN28 acts as an independent
prognostic factor for GBM patients. The in vitro experiments
indicated that LIN28 can increase U251 and U373 cell growth
and enhance the colony formation ability. Furthermore, LIN28
promotes cell cycle progression from G1 to S phase and
increases the percentage of cells in G2/M. Moreover, LIN28
inhibits glioma cell apoptosis. Taken together, these results
indicate that LIN28 may be an oncogene and promotes glioma
cell growth mainly through the promotion of cell cycle
progression and inhibition of cell apoptosis.
Dysfunction of cell cycle and apoptosis regulation plays an
important role in the development of a tumor, including glioma.
In the three main signaling pathways defined by the TCGA group,
the RB and p53 pathway are critical for regulating the cell cycle,
while the p53 pathway is also associated with cell apoptosis. It has
been shown that LIN28 can modulate the transcription of CDK4
in the RB pathway, and more recently, bioinformatics analysis
found that p53 may increase the expression of let-7, which could
suppress the expression of LIN28 [32]. However, the precise
molecular mechanisms involved in the p53 and LIN28 interaction
in glioma are currently unknown and will require further
experimentation.
Many studies have focused on targeted molecular therapies,
but the results are disappointing with relatively rare radio-
graphic responses and no significant prolongation of PFS
reported in GBM [33,34]. This is partially due to the
coactivation of several signaling pathways during glioma
development. Therefore, identification of new targets, especially
those involved in the three core pathways responsible for GBM
development, is of utmost importance. Because LIN28 has been
shown to be involved in each of these three pathways, the
development of therapeutics targeting this factor may provide
improved efficacy for treating GBM. In addition, LIN28 is a
stem cell reprogramming factor, and thus agents targeting
LIN28 may also target glioma stem cells.
In conclusion, we have demonstrated that high expression of
LIN28 in glioma is associated with a shorter median OS and PFS
and that LIN28 might be a predictor of prognosis in GBM
patients, thus serving as an independent prognostic factor. In
addition, suppression of LIN28 reduced the growth of glioma cells
and promoted apoptosis. Its involvement in the three core
signaling pathways involved in GBM makes it a potential target
for cancer therapy as an approach to overcome the poor options
currently available for these patients.
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